natgillin/translations-raw huggingface dataset:
60 mg lyserøde, runde tabletter med skrå kant præget med ”NVR” på den ene side og med ”TS” på den anden side.
60 mg pink, round, bevelled-edge tablets with “NVR” marked on one side and “TS” on the other.
60 mg N=65 n (%), p-værdi
N=65 n (%), p value
60 mg én gang dagligt
60 mg once daily
60 mg/m2 i.v. (1 time), dag 1-5
VM26 60 mg/m2 i.v. (1 h), days 1-5
60 mikrogram ETIKET TIL FYLDT INJEKTIONSSPRØJTE
60 micrograms PRE-FILLED SYRINGES LABEL
60 mikrogram pr. m2 legemsoverfladeareal (beregnet ud fra patientens højde og vægt).
60 micrograms per square metre body surface area (calculated using the patient’s height and weight).
60 millioner IE injektionsvæske flerdosispen 1 pen, 12 kanyler og 12 renseservietter
60 million IU solution for injection multidose pen 1 pen, 12 injection needles and 12 cleansing swabs
60 millioner IE injektionsvæske i flerdosispen 1 pen, 12 kanyler og 12 renseservietter 2 penne, 24 kanyler og 24 renseservietter 8 penne, 96 kanyler og 96 renseservietter
60 million IU solution for injection in multidose pen 1 pen, 12 injection needles and 12 cleansing swabs 2 pens, 24 injection needles and 24 cleansing swabs 8 pens, 96 injection needles and 96 cleansing swabs
60 millioner IE/pen
60 million IU/pen
60 minutter efter subkutan injektion af 0,30 enheder/kg legemsvægt.
60 minutes after a subcutaneous dose of 0.30 unit/kg body weight.
60 minutter.
The drip lasts about 60 minutes.
60 minutters intravenøs infusion hos raske forsøgspersoner i 7 dage.
60 minute intravenous infusion for 7 days in healthy volunteers.
60 ml eller 75 ml*
60 ml or 75 ml
60 ml HDPE-medicinglas med induktionsforseglede, børnesikrede polypropylenlåg; 60 filmovertrukne tabletter pr. medicinglas.
60 ml HDPE bottles with induction-sealed, polypropylene child-resistant caps; 60 film-coated tablets per bottle.
60 ml infusionspose
60 ml infusion bag
60 ml plastik-medicinglas med børnesikret induktionsforsegling; 60 filmovertrukne tabletter pr. medicinglas.
60 ml plastic bottles capped with child-resistant induction seal closure; 60 film-coated tablets per bottle.
60 ml pr. pose
60 ml per bag
60 ml/min/1,73 m2 eller CrCl til under 60 ml/min, bør doseringen af canagliflozin justeres til eller opretholdes på 100 mg en gang dagligt.
60 mL/min/1.73 m2 or CrCl 60 mL/min, the dose of canagliflozin should be adjusted to or maintained at 100 mg once daily.
60 måneder 76,4% (70,8-81,5)
60 months 76.4% (70.8-81.5)
60 måneder ved 2 °C – 8 °C.
60 months at 2 °C - 8 °C.
60 måneder ved 2 °C – 8 °C.
60 months at 2°C – 8°C.
60 pust
60 sprays
60 resoribletter
60 tablets
60 smeltetabletter
60 orodispersible tablets
60 tabletten
60 tablets
60 tabletter i en plastbeholder.
60 tablets in a plastic bottle.
60 tabletter: EU/1/08/469/003
60 tablets: EU/1/08/469/003
60 tabletter: EU/1/08/469/008
60 tablets: EU/1/08/469/008
60 tabletter: EU/1/08/469/013
60 tablets: EU/1/08/469/013
60 tabletter: EU/1/08/469/018
60 tablets: EU/1/08/469/018
60 tabletter: EU/1/08/469/023
60 tablets: EU/1/08/469/023
60 tabletter: EU/1/11/721/005
60 tablets: EU/1/11/721/005
60 tabletter: EU/1/11/721/012
60 tablets: EU/1/11/721/012
60 tabletter: EU/1/11/721/019
60 tablets: EU/1/11/721/019
60 tabletter: EU/1/11/723/005
60 tablets: EU/1/11/723/005
60 tabletter: EU/1/11/723/012
60 tablets: EU/1/11/723/012
60 tabletter: EU/1/11/723/019
60 tablets: EU/1/11/723/019
60 x 1 bløde kapsler
60 x 1 soft capsule
60 x 1 bløde kapsler i aluminium/aluminiumsperforerede enkeltdosisblistere Begge pakningsstørrelser er ikke nødvendigvis markedsført.
60 x 1 soft capsules in Aluminium/aluminium perforated unit dose blisters Not all pack sizes may be marketed.
60 x 1 bløde kapsler i aluminium/aluminiumsperforerede enkeltdosisblistere Begge pakningsstørrelser er ikke nødvendigvis markedsført.
60 x 1 soft capsules in Aluminium/aluminium perforated unit dose blisters Not all pack-sizes may be marketed.
60 x 1 bløde kapsler.
60 x 1 soft capsule.
60 x 1 filmovertrukne tabletter
60 X 1 film-coated tablet
60 x 1 filmovertrukne tabletter
60 x 1 film-coated tablets
60 x 1 filmovertrukne tabletter.
60 x 1 film-coated tablets.
60 x 1 hårde kapsler.
60x1 hard capsules.
60 x 1 kapsler
60 x 1 capsules
60 x 1 kapsler (enkeltdosis)
60 x 1 capsules (unit dose)
60 x 1 smeltetablet
60 x 1 orodispersible tablet
60 x 1 smeltetablet: EU/1/09/525/030
60 x 1 orodispersible tablet:EU/1/09/525/030
60 x 1 smeltetablet: EU/1/09/525/035
60 x 1 orodispersible tablet:EU/1/09/525/035
60 x 1 smeltetablet: EU/1/09/525/040
60 x 1 orodispersible tablet:EU/1/09/525/040
60 x 1 smeltetablet: EU/1/09/525/045
60 x 1 orodispersible tablet:EU/1/09/525/045
60 x 1 tablet
60 x 1 tablets (unit dose)
60 x 1 tablet (enhedsdosis)
60 x 1 tablet (unit dose)
60 x 1 tablet (enkeltdosis)
60 x 1 tablet
60 x 1 tablet (enkeltdosis)
60 x 1 tablet (unit
60 x 1 tablet (enkeltdosis)
60 x 1 tablet (unit dose)
60 x 1 tablet (enkeltstyk)
60 x 1 tablet (unit dose)
60 x 1 tabletter (enhedsdosis)
60x1 tablets (unit dose)
60 x 1 tabletter (enkeltdosis)
60 x 1 tablets (unit dose)
60 x 1 tabletter (enkeltsdosis)
60 x 1 tablet (unit dose)
60 x 1, 84 x 1, 90 x 1, 98 x 1, 100 x 1 og 120 x 1 filmovertrukne tabletter.
84 x 1, 90 x 1, 98 x 1, 100 x 1 and 120 x 1 film-coated tablets.
60 µg
10 µg
60 µg
150 µg
60 µg
500 µg
60 µg
80 µg
60 år og derover Efter 21 dage
60 years and above 21 Days After
60% (0,6 IE/ml)
60 % (0.6 IU/ml)
60% til 70%.Telithromycin fordeles bredt i hele kroppen.
Telithromycin is widely distributed throughout the body.
60, 100 eller 200 tabletter.
30, 50, 60, 100 and 200 tablets per pack.
60,0 til 63,5
60.0 to 63.5
60,3 mg (S)- methopren, 80 mg amitraz
60 3 mg (S)- methoprene, 80 mg amitraz
60,3 mg (S)- methopren, 80 mg amitraz
60.3 mg (S)- methoprene, 80 mg amitraz
60,4% af de patienter, der blev behandlet med Xultophy, nåede et mål på HbA1c <7% uden bekræftede hypoglykæmiske episoder efter 26 ugers behandling.
60.4% of patients treated with Xultophy reached a target of HbA1c <7% without confirmed hypoglycaemic episodes after 26 weeks of treatment.
60,7 ng/ml og 12,0 t.
60.7 ng/mL and 12.0 h respectively.
60-100 (startniveau)
60 - 100 (initial level)
60-130 mg en gang dagligt
from 60 mg to 130 mg
60-322 Poznan Polen
60-322 Poznan Poland
60-64 år
60-64 Years
60-70
60 to 70
60-75 minutt er (ml/t)
60-75 minutes (ml/hr)
60-79,9 kg
60 to 79.9 kg
60-80 L/min.
60-80 mL/min.
60-89 ml/min/1,73m2) sammenlignet med patienter med normal nyrefunktion.
60-89 mL/min/1.73m2) and patients with normal renal function.
60-mg-tabletterne og 120-mg- tabletterne må kun anvendes til hunde, og Veraflox oral suspension må kun anvendes til katte.
The 60 mg and 120 mg tablets are only for use for dogs, and Veraflox oral suspension is only for use in cats.
60.165 (38.627 – 80.764) E*t/l
60,165 (38,627 – 80,764) U*h/l
600 IE (44 g)/hætteglas
600 IU (44 g)/vial
600 IE*** human von Willebrand-faktor** (VWF)
600 IU*** human von Willebrand factor** (VWF).
600 IE/0,72 ml
600 IU/0.72 mL
600 IE/ml efter rekonstituering).
600 IU/ml after reconstitution).
600 IE/ml efter rekonstitution med 5 ml solvens.
600 IU/ml after reconstitution with 5 ml solvent.
600 IU/ml efter rekonstitution)
600 IU/mL after reconstitution)
600 mg (30 ml) 1 gang dagligt
600 mg (30 ml) once daily
600 mg (6 ml) PREZISTA/100 mg (1,2 ml) ritonavir to gange dagligt
600 mg (6 ml) PREZISTA/100 mg (1.2 ml) ritonavir twice daily
600 mg (kropsvægt 600 kg)
600 mg (600 kg bodyweight)
600 mg 1 gang dagligt
600 mg once daily
600 mg 1 gang hver 48. time
600 mg once every 48 hours
600 mg 1 gang hver 72. time
600 mg once every 72 hours
600 mg 1 gang hver 96. time
600 mg once every 96 hours
600 mg 4 gange daglig
600 mg QD
600 mg 4 gange dagligt
600 mg QD
600 mg amprenavir to gange daglig med 100 mg ritonavir to gange daglig.
Amprenavir 600 mg twice daily with ritonavir 100 mg twice daily.
600 mg eller 8 mg/kg hver 8. uge
600 mg or 8 mg/kg every 8 weeks
600 mg en gang daglig
600 mg once daily
600 mg i den 3. uge, derefter 600 mg hver 2. uge
600 mg at week 3; then 600 mg every 2 weeks
600 mg i uge 3, derefter 600 mg hver 2. uge
600 mg at week 3; then 600 mg every 2 weeks
600 mg prednisolon
600 mg prednisolone
600 mg prednisolon (brev, 18 g)
600 mg prednisolone (18 g sachet)
600 mg PREZISTA (2 tabletter a 300 mg PREZISTA eller 1 tablet a 600 mg PREZISTA) sammen med 100 mg ritonavir to gange dagligt
600 milligram PREZISTA (2 tablets containing 300 milligram of PREZISTA or 1 tablet containing 600 milligram of PREZISTA) together with 100 milligram ritonavir twice daily.
600 mg PREZISTA (2 tabletter a 300 mg PREZISTA eller 1 tablet a 600 mg PREZISTA) sammen med 100 mg ritonavir to gange dagligt.
600 milligram PREZISTA (2 tablets containing 300 milligram of PREZISTA or 1 tablet containing 600 milligram of PREZISTA) together with 100 milligram ritonavir twice daily.
600 mg PREZISTA + 100 mg ritonavir to gange dagligt
600 milligram PREZISTA + 100 milligram ritonavir twice a day
600 mg PREZISTA sammen med 100 mg ritonavir to gange dagligt.
600 milligram PREZISTA together with 100 milligram ritonavir twice daily.
600 mg PREZISTA/100 mg ritonavir to gange dagligt
600 mg PREZISTA/100 mg ritonavir twice daily
600 mg som skal tages som én kapsel af 400 mg plus 2 kapsler af 100 mg én gang daglig.
600 mg to be taken as 1 capsule of 400 mg plus 2 capsules of 100 mg once a day.
600 mg som skal tages som én tablet af 400 mg plus 2 tabletter af 100 mg én gang daglig.
600 mg to be taken as 1 tablet of 400 mg plus 2 tablets of 100 mg once a day.
600 mg som skal tages som én tablet af 400 mg plus 2 tabletter af 100 mg én gang daglig.
600 mg to be taken as one tablet of 400 mg plus 2 tablets of 100 mg once a day.
600 mg to
600 mg twice
600 mg to gange daglig
600 mg twice daily
600 mg ugentligt x 1
600 mg weekly x 1
600 mg ugentligt x 2
600 mg weekly x 2
600 mg x 1
200 mg twice daily
600 mg x 1
600 mg once daily
600 mg én gang daglig
600 mg once daily
600 mg én gang dagligt
600 mg once daily
600 mg)
aANC <0.5x109/1
600 mg/ m2 intravenøst 22 timer
bolus, followed by 600 mg/ m2 intravenous 22 hr
600 mg/1920 mg og 900 mg/2880 mg).
300 mg/960 mg, 600 mg/1920 mg and 900 mg/2880 mg).
600 mg/m2 intravenøs
600 mg/m2
600 mikrogram
600 micrograms
600 x109/l eller en  50% reduktion i forhold til baseline og opretholdelse af reduktionen i mindst 4 uger.
 50% reduction from baseline and maintenance of the reduction for at least 4 weeks.
600 μmol/l er forbundet med en meget stor incidens af neurologiske anomalier, hjerte- og vækstanomalier samt ansigtsdysmorfi.
PKU-affected women demonstrated that uncontrolled phenylalanine levels above 600 μmol/l are associated with a very high incidence of neurological, cardiac, facial dysmorphism, and growth anomalies.
600.000 IE/ml
≤ 600,000 IU/ml
600/100 mg to gange
600/100 mg twice daily
600/100 mg to gange dagligt
twice daily
600/100 mg to gange dagligt og
other than 600/100 mg twice daily
600/100 mg x 1
600/100 mg QD
6000 IE /
6000 IU/0.6 ml
6013329, Packard Instruments, USA eller tilsvarende)
6013329, Packard Instruments, USA or equivalent)
6013329, Packard Instruments, USA eller tilsvarende).
6013329, Packard Instruments, USA or equivalent).
6036 patienter, der blev behandlet for STEMI AKS
6,036 patients undergoing treatment of STEMI ACS.
6036 patienter, der blev behandlet for STEMI AKS.
6,036 patients undergoing treatment of STEMI ACS.
604 patienter randomiseredes til behandling med 5-FU og leucovirin (Mayo regime: 20 mg/m2 leucovirin i.v. efterfulgt af en 5-FU bolus på 425 mg/m2 i.v. på dag 1 til 5, hver 28. dag).
604 patients were randomised to treatment with 5-FU and leucovorin (Mayo regimen: 20 mg/m2 leucovorin IV followed by 425 mg/m2 IV bolus 5-FU, on days 1 to 5, every 28 days).
606 (301-911) totale antigen masseenheder af opløseligt parasitantigen (SPA) fra Babesia canis og
606 (301-911) total antigenic mass units of soluble parasite antigen (SPA) from Babesia canis and
606(301-911) totale antigene Masse-enheder
911) total antigenic mass units
60hårde kapsler: EU/1/03/267/001
60 hard capsules: EU/1/03/267/001
60hårde kapsler: EU/1/03/267/003
60 hard capsules: EU/1/03/267/003
60x1 tabletter
60x1 tablets
60x1 tabletter (enhedsdosis)
60x1 tablets (unit dose)
60×1 kapsel
60×1 capsule
61 (42)
Bzmb n=187
61 patienter fik behandling med startdosen på 300 mg/m2/dag.
Sixty-one patients were treated at the starting dose of 300 mg/m2/day.
61 patienter fuldførte forsøget (35 patienter fik den anbefaldede dosis 400/100 mg gennem hele studiet).
Sixty-one patients completed the study (35 patients received the recommended 400/100 mg twice-daily dose throughout the study).
61 patienter fuldførte studiet (35 patienter fik den anbefaldede dosis 400/100 mg gennem hele studiet).
Sixty-one patients completed the study (35 patients received the recommended 400/100 mg twice daily dose throughout the study).
61 til 70 år
61 to 70 years
61% (N = 485) af alle randomiserede patienter fik fluorpyrimidin, som en del af deres sidste behandlingsregime før randomisering, hvor (94%) var resistente overfor fluorpyrimidin på dette tidspunkt.
Sixty one percent (61%, N = 485) of all randomised patients received a fluoropyrimidine as part of their last treatment regimen prior to randomisation, of which 455 (94%) were refractory to the fluoropyrimidine at that time.
61% af patienterne havde sygdomsstadie M1c ved inklusion i studiet.
Sixty-one percent of patients had M1c stage disease at study entry.
61, D-81673 München, Tyskland.
61, D-81673 München, Germany.
61-70 kg
61 – 70
61-70 år
61 to 70 years
61-70 år
61-70 years
6167 RD Geleen Holland
6167 RD Geleen Netherlands
62 gange den maksimale kliniske eksponering for empagliflozin.
1,000 mg/kg/day, which corresponds to approximately 62-times the maximal clinical exposure to empagliflozin.
62 gange den maksimale kliniske eksponering for empagliflozin.
1000 mg/kg/day, which corresponds to approximately 62-times the maximal clinical exposure to empagliflozin.
62% (95% CI: 44; 75) og 56% (95% CI: 39; 70) for ipilimumab alene.
CI: 39, 70) respectively for ipilimumab.
62,4b
62.4b
62,9 % af patienterne i Gruppe II behøvede ingen injektioner i de sidste 6 måneder af studiet.
62.9% of Group II patients did not require injections in the second 6 months of the study.
62.5 IE/ml efter rekonstitution)
62.5 IU/ml after reconstitution).
62010 Montecosaro (MC) - Italien
62010 Montecosaro (MC) – Italy
62010 Montecosaro (MC) - Italien Tel:0039.388.8735530 or 0039.0733.560354
62010 Montecosaro (MC) – Italy
62010 Montecosaro (MC) – Italien
62010 Montecosaro (MC) – Italy
6221 CB Maastricht Holland
6221 CB Maastricht The Netherlands
6250 Kundl Østrig
6250 Kundl Austria
62660 Beuvry Frankrig
62660 Beuvry France
63 filmovertrukne tabletter
63 film-coated tablets
63 patienter fik en oral initialdosis på 50 mg sunitinib 1 gang dagligt i 4 på hinanden følgende uger efterfulgt af 2 ugers pause for at fuldføre en fuldstændig cyklus på 6 uger (doseringsskema 4/2).
Sixty-three patients received a starting dose of 50 mg sunitinib orally, once daily for 4 consecutive weeks followed by a 2-week rest period, to comprise a complete cycle of 6 weeks (schedule 4/2).
63 ud af de 100 patienter, der blev inkluderet i del II, og som fik enten placebo eller canakinumab, oplevede ikke udbrud i observationsperioden (op til maksimalt 80 uger).
Sixty-three of the 100 patients entering part II, whether assigned to placebo or canakinumab, did not experience a flare over the observation period (up to a maximum of 80 weeks).
63% (1.139/1,817) var 75 år eller ældre.
63% (1,139/1,817) were 75 years of age or older.
63,6 til 67,2
63.6 to 67.2
63,6 ± 30,1 ng.t/ml.
26.0 ± 12.0 ng.h/ml and 63.6 ± 30.1 ng.h/ml respectively.
63,9 % til 95,5 %
63.9% to 95.5
63-81 High Street Rickmansworth Hertfordshire WD3 1EQ Storbritannien
63-81 High Street Rickmansworth Hertfordshire WD3 1EQ United Kingdom
63/396 (16 %) af patienterne med adenocarcinom histologitype er M+ 12/390 (3 %) af patienterne der ikke har adenocarcinom histologitype er M+ 40/235 (17 %) af kvinderne er M+ 35/551 (6 %) af mændene er M+
63/396 (16%) of patients with adenocarcinoma histology are M+ 12/390 (3%) of patients with non-adenocarcinoma histology are M+ 40/235 (17%) of females are M+ 35/551 (6%) of males are M+
63800 Cournon d’Auvergne Frankrig
63800 Cournon d’Auvergne France
63800 Courron d‘Auvergne Frankrig
63800 Courron d‘Auvergne France
63963 Clermont-Ferrand Cedex 9 Frankrig
63963 Clermont-Ferrand Cedex 9 France
63–81 High Street Rickmansworth Hertfordshire WD3 1EQ Storbritannien
63–81 High Street Rickmansworth Hertfordshire WD3 1EQ United Kingdom
64 % (n=209)
64% (n=209)
64 % af personerne, der deltog i ENABLE 1 og ENABLE 2, var genotype 1. f Post-hoc-analyser
64% subjects participating in ENABLE 1 and ENABLE 2 were genotype 1 f Post-hoc analyses
64 patienter med CLL blev inkluderet i studiet på et hvilket som helst tidspunkt i deres behandling med intravenøs MabThera i kombination med kemoterapi.
A number of 64 patients with CLL were enrolled at any point during their treatment with MabThera intravenous formulation in combination with chemotherapy.
64% af patienterne havde ingen klinisk gavn (CR/PR eller SD) af tidligere behandling med ipilimumab.
Sixty-four percent of patients had no prior clinical benefit (CR/PR or SD) on ipilimumab.
64% af patienterne var mænd, og 98% var kaukasiere.
Sixty-four percent of patients were men and 98% were white.
64,2% (44,2; 77,3)e
64.2% (44.2, 77.3)e
64,3 % af pemetrexed- patienterne og 71,7 % af placebo-patienterne fik behandling efter studiet.
The percentage of patients that received post study treatment was 64.3% for pemetrexed and 71.7% for placebo.
64,5 (544/844)
IGlar
64,9 % (24/37)b
64.9% (24/37)b
64,9 (45,7-
64.9 (45.7 to
64-77 % af fondaparinux udskilles uændret via nyrerne.
Fondaparinux is excreted to 64 – 77 % by the kidney as unchanged compound.
6422 PJ Heerlen Holland
6422 PJ Heerlen The Netherlands
64293 Darmstadt Tyskland
64293 Darmstadt Germany
64331 Weiterstadt, Tyskland
64331 Weiterstadt, Germany
645 41 Strängnäs Sverige
645 41 Strängnäs Sweden
64Cu er en beta-emitter.
64Cu is a beta emitter.
64Cu er en radio- aktiv form af kobber.
64Cu is a radioactive form of copper.
64Cu-mærkede lægemidler bør ikke anvendes til børn og unge under 18 år.
64Cu-labelled medicinal products should not be used in children and adolescents up to 18 years.
65 % (n=237)
65% (n=237)
65 % placebo efter 26 uger, 55 % NB vs.
65% Placebo at 26 Weeks, 55% NB vs.
65 (56; 72)
Baseline Characteristic
65 patienter indgik i et opfølgningsstudie med op til 28 ugers yderligere behandling.
Sixty-five patients entered a follow-up SBS study for up to an additional 28 weeks of treatment.
65 procent af patienterne undersøgt i et SCN forsøgsprogram med filgrastim administration, var under 18 år.
Sixty-five percent of patients studied in a SCN trial program with filgrastim administration, were under 18 years of age.
65 procent af patienterne undersøgt i et SCN forsøgsprogram var under 18 år.
Sixty-five percent of patients studied in a SCN trial program, were under 18 years of age.
65 procent af patienterne, undersøgt i et SCN-forsøgsprogram med filgrastim-administration, var under 18 år.
Sixty-five percent of patients studied in a SCN trial program with filgrastim administration, were under 18 years of age.
65 quai Georges Gorse, 92100 Boulogne-Billancourt, Frankrig
65 quai Georges Gorse 92100 Boulogne-Billancourt France
65 ud af 88 patienter gennemførte forlængelsesstudiet.
65 of 88 patients completed the extension study.
65 år eller ældre: tag en 5 mg kapsel
65 or older: Take one 5 mg capsule
65 år.
65 years.
65 ≤ og < 75
65 ≤ and < 75
65% af patienterne, der blev undersøgt i SCN-studieprogrammet, var under 18 år.
Sixty-five percent of the patients studied in the SCN trial program were under 18 years of age.
65%; p < 0,0001
65%; P < .0001
6545 CG Nijmegen Holland
6545 CG Nijmegen Netherlands
6545 CG Nijmegen Holland (Tlf.) +31 24 371 7310
6545 CG Nijmegen Netherlands (Tel) +31 24 371 7310
6545 CG Nijmegen Nederlandene
6545 CG Nijmegen Netherlands
6545 CG Nijmegen, Holland
6545 CG Nijmegen, The Netherlands
66 % (n=235)
66% (n=235)
66 % af patienterne i placebo-armen fik behandling efter studiet sluttede sammenlignet med 30 % af patienterne i pazopanib-armen.
Sixty-six percent of placebo patients received post-study therapy compared to 30 % of pazopanib patients.
66 mikrogram (18 millioner IE)/1,5 ml.
66 micrograms (18 million IU)/1.5 mL
66%; p < 0,0001
66%; P < .0001
66,6 (42,0 til -)
66.6 (42.0 to -)
662 patienter, der var egnede til at deltage i den dobbeltblindede, aktivkontrollerede fase over 38 uger, blev randomiseret i forholdet 2:2:1 til dobbeltblindet behandling i en af følgende tre behandlingsgrupper: 1) Abilify Maintena, 2) stabiliseringsdosis af oralt aripiprazol 10-30 mg eller 3) aripiprazol-depotinjektion 50 mg/25 mg.
Six-hundred and sixty two patients eligible for the 38-week Double-blind, Active-controlled Phase were randomly assigned in a 2:2:1 ratio to double-blind treatment to one of 3 treatment groups: 1) Abilify Maintena 2) the stabilisation dose of oral aripiprazole 10-30 mg, or 3) aripiprazole Long- Acting Injectable 50 mg/25 mg.
667 IU/ml efter rekonstitution)
667 IU/mL after reconstitution)
66d [59-72]
66d [59,72]
67 % (n=197)
67% (n=197)
67 % af patienterne oplevede mindst én infusionsrelateret reaktion.
Sixty seven percent (67%) of the patients experienced at least one infusion-associated reaction.
67 % sammenlignet med en kontrolgruppe af patienter.
10 mg/dl) decreased to about 67 % when compared with a control group of patients.
67 HBeAg-positive patienter og 1 HBeAg-negativ patient med samtidig hiv-infektion.
HIV/HBV co-infected patients receiving concomitant HAART: study 038 included 67 HBeAg positive and 1 HBeAg negative patients co-infected with HIV.
67%; p < 0,0001
67%; P < .0001
67,2 mikrogram
67.2 micrograms
67,3 til 70,8
67.3 to 70.8
67,4±36,9
CLRENAL
67,6 %
Diff
67-106 ng/ml for en dosis på 1,0 mg/m2 og på 89-120 ng/ml for en dosis på 1,3 mg/m2.
1.0 mg/m2 dose and 89 to 120 ng/ml for the 1.3 mg/m2 dose.
67019 Scoppito (AQ) Italien
67019 Scoppito (AQ) Italy
6705 eksponering kan ses ved
DM-6705 exposure may be
675 mg (6,8 ml)
675 milligram (6.8 milliliter)
675 mg (6,8 ml)b PREZISTA/100 mg (1,2 ml) ritonavir en gang dagligt
675 mg (6.8 ml)b PREZISTA/100 mg (1.2 ml) ritonavir once daily
678 01 Blansko Tjekkiet
678 01 Blansko Czech Republic
67801 Blansko Tjekkiet
67801 Blansko Czech Republic
68 % af hydrochlorthiazidet er bundet i plasma, og det tilsyneladende fordelingsvolumen er 0,83-1,14 l/kg.
Hydrochlorothiazide is 68 % protein bound in the plasma and its apparent volume of distribution is 0.83-1.14 l/kg.
68 % af patienterne havde en ECOG-funktionsscore på 0, og 32 % af patienterne havde en ECOG-funktionsscore på 1.
Sixty-eight percent (68%) of patients had an ECOG performance status score of 0 and 32% patients had ECOG performance status 1.
68 — 82%) udskilles via fæces.
68 - 82%) is excreted via the faeces.
68% (21/31) af de antistofpositive patienter havde neutraliserende antistoffer in vitro.
Sixty-eight percent (21/31) of antibody- positive patients had neutralising antibodies in vitro.
68% af hydrochlorthiazidet er bundet i plasma, og det tilsyneladende fordelingsvolumen er 0,83- 1,14 l/kg.
Hydrochlorothiazide is 68 % protein bound in the plasma and its apparent volume of distribution is 0.83 – 1.14 l/kg.
68% af hydrochlorthiazidet er bundet i plasma, og det tilsyneladende fordelingsvolumen er 0,83-1,14 l/kg.
Hydrochlorothiazide is 68 % protein bound in the plasma and its apparent volume of distribution is 0.83 – 1.14 1/kg.
68% af hydrochlorthiazidet er bundet i plasma, og det tilsyneladende fordelingsvolumen er 0,83-1,14 l/kg.
Hydrochlorothiazide is 68 % protein bound in the plasma and its apparent volume of distribution is 0.83 – 1.14 l/kg.
68,0 mg/tablet
68.0 mg/tablet
683 23 Ivanovice na Hané DEN TJEKKISKE REPUBLIK
683 23 Ivanovice na Hané, CZECH REPUBLIC
683 23 Ivanovice na Hané DEN TJEKKISKE REPUBLIK
683 23, Ivanovice na Hané, CZECH REPUBLIC
683 23 Ivanovice na Hané TJEKKIET
683 23 Ivanovice na Hané, CZECH REPUBLIC
69,2 %
46.9% (p=0.006)
69,3 %, nedre konfidensgrænse -11,9 %).
69.3 % respectively, lower confidence bound -11.9%).
69,4 % (95 % CI: 54,6;81,7)
69.4% (95% CI: 54.6;81.7)
69,4 % (n=209)
69.4% (n=209)
69,5 % (n=197)
69.5 % (n=197)
69,5 (58,67 til -)
69.5 (58.6 to -)
69,6 % til 98,8 %
69.6% to 98.8